Tempus AI (TEM) announced the national launch of the company’s FDA-approved, NGS-based in vitro diagnostic device, xT CDx. Beginning today, xT CDx is now available for all ordering clinicians ...
The stock is showing a significant uptick gaining over 169% this year. Tempus AI, Inc. (NASDAQ:TEM) has launched a new xT CDx, an FDA-approved Next-Generation Sequencing in vitro diagnostic device ...